	US 12,258,372 B2
	Recombinant vaccine against Marek's disease and Newcastle disease
Qingzhong Yu, Athens, GA (US); Stephen J. Spatz, Bogart, GA (US); and John R. Dunn, East Lansing, GA (US)
Assigned to The United States of America, as represented by The Secretary of Agriculture, Washington, DC (US)
Filed by The United States of America, as represented by the Secretary of Agriculture, Washington, DC (US)
Filed on Feb. 28, 2022, as Appl. No. 17/682,358.
Application 17/682,358 is a continuation of application No. 16/848,880, filed on Apr. 15, 2020, granted, now 11,299,517.
Prior Publication US 2022/0185848 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/125 (2006.01); A61K 35/76 (2015.01); A61K 39/17 (2006.01); C07K 14/055 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/125 (2013.01) [C07K 14/055 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01)]

10 Claims

1. A recombinant Newcastle disease virus (NDV), comprising a synthetic polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:2, and wherein the genome of the recombinant NDV is at least 95% identical to SEQ ID NO: 3.